Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 21;331(19):1668-1669.
doi: 10.1001/jama.2024.2667.

APOL1-Mediated Kidney Disease

Timothy Hopper  1 , Opeyemi A Olabisi  1   2
Affiliations

APOL1-Mediated Kidney Disease

Timothy Hopper et al. JAMA. .
No abstract available

Plain language summary

This JAMA Insights reviews the origin of APOL1 high-risk genetic variants, defines APOL1-mediated kidney disease, and discusses recommendations for screening and management.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Olabisi reported grants from NIH during the conduct of the study. No other disclosures were reported.

Figures

Figure.
Figure.. APOL1-Mediated Kidney Disease in Black Individuals in the US
Bubble plot shows the odds ratio of APOL1-mediated kidney disease (AMKD) in Black individuals in the US with a high-risk APOL1 genotype compared with Black individuals with a low-risk APOL1 genotype. The area of each bubble represents the population attributable risk—the proportion of the incidence of each type of kidney disease that is attributed to high-risk APOL1 genotype. Odds ratios from Friedman and Pollak. Estimated number of affected individuals was extrapolated from United States Renal Data System. Population attributable risk was calculated from odds ratio and the frequency of high-risk APOL1 genotype in the Black US population. CKD indicates chronic kidney disease; HTN-ESKD, hypertension-attributed end-stage kidney disease; and FSGS, focal segmental glomerulosclerosis.
See this image and copyright information in PMC

Comment in

References

    1. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010; 329(5993):841–845. doi:10.1126/science.1193032 - DOI - PMC - PubMed
    1. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129–2137. doi:10.1681/ASN.2011040388 - DOI - PMC - PubMed
    1. Friedman DJ, Pollak MR. APOL1 nephropathy: from genetics to clinical applications. Clin J Am Soc Nephrol. 2021;16(2):294–303. doi:10.2215/CJN.15161219 - DOI - PMC - PubMed
    1. Nadkarni GN, Gignoux CR, Sorokin EP, et al. Worldwide frequencies of APOL1 renal risk variants. N Engl J Med. 2018;379(26):2571–2572. doi:10.1056/NEJMc1800748 - DOI - PMC - PubMed
    1. Egbuna O, Zimmerman B, Manos G, et al.; VX19-147-101 Study Group. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N Engl J Med. 2023;388(11):969–979. doi:10.1056/NEJMoa2202396 - DOI - PubMed

Publication types

MeSH terms